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Background. The burden and timeline of posttransplant infections are not comprehensively documented in the current era of 
immunosuppression and prophylaxis.
Methods. In this prospective study nested within the Swiss Transplant Cohort Study (STCS), all clinically relevant infections 
were identified by transplant–infectious diseases physicians in persons receiving solid organ transplant (SOT) between May 2008 
and December 2014 with ≥12 months of follow-up.
Results. Among 3541 SOT recipients, 2761 (1612 kidney, 577 liver, 286 lung, 213 heart, and 73 kidney-pancreas) had ≥12 months 
of follow-up; 1520 patients (55%) suffered 3520 infections during the first year posttransplantation. Burden and timelines of clinically 
relevant infections differed between transplantations. Bacteria were responsible for 2202 infections (63%) prevailing throughout the 
year, with a predominance of Enterobacteriaceae (54%) as urinary pathogens in heart, lung, and kidney transplant recipients, and 
as digestive tract pathogens in liver transplant recipients. Enterococcus spp (20%) occurred as urinary tract pathogens in kidney 
transplant recipients and as digestive tract pathogens in liver transplant recipients, and Pseudomonas aeruginosa (9%) in lung trans-
plant recipients. Among 1039 viral infections, herpesviruses predominated (51%) in kidney, liver, and heart transplant recipients. 
Among 263 fungal infections, Candida spp (60%) prevailed as digestive tract pathogens in liver transplant recipients. Opportunistic 
pathogens, including Aspergillus fumigatus (1.4%) and cytomegalovirus (6%), were rare, scattering over 12 months across all SOT 
recipients.
Conclusions. In the current era of immunosuppression and prophylaxis, SOT recipients experience a high burden of infections 
throughout the first year posttransplantation, with rare opportunistic pathogens and a predominance of bacteria.
Keywords.  infection; bacterial; fungal; viral; solid organ transplant.
Solid organ transplant (SOT) recipients require long-term 
immunosuppression and are at risk for life-threatening infec-
tions. Three periods of infections after transplantation have 
been distinguished: (1) a phase up to 1  month characterized 
by nosocomial infections and donor-derived infections; (2) a 
phase of profound immunosuppression for up to 6 months as-
sociated with opportunistic infections; and (3) a phase of re-
duced immunosuppression with community-acquired and rare 
infectious agents [1–3].
The awareness of this temporal pattern has allowed tailoring 
of prophylactic strategies, diagnostic testing, and empiric ther-
apies. Since the review of this concept in 1998, new potent 
immunosuppressive strategies have reduced the incidence of 
rejection, but at the same time altered recipients’ susceptibility 
to infections. Concomitantly, the availability of efficient pro-
phylaxis may have modified frequencies and temporal patterns 
of posttransplant infections [2, 4–6]. Knowledge of timing and 
relative frequencies of infections in the era of extended donor/
recipient criteria, modern immunosuppression, routine use 
of prophylaxis, and active surveillance of viral replication is 
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crucial for implementing prevention strategies to further re-
duce morbidity and mortality associated with posttransplant 
infections. Registries provide important data in this regard but 
are restricted by a limited number of selected infections, and 
lack both stringent patient follow-up and standardized defin-
itions of infections. Only a few studies have prospectively and 
comprehensively recorded the incidence of specific infections 
and been able to estimate the relative burden and timeline pat-
terns of certain pathogens [4, 5, 7].
Since May 2008, the Swiss Transplant Cohort Study (STCS) 
has enrolled 93% of all SOT recipients in Switzerland, and pro-
vides an ideal source to extract data on all aspects of trans-
plantation including infections. Using prespecified rigorous 
definitions [8] and transplant center review, we analyzed com-
prehensive data on 3520 clinically relevant infections occurring 
in the first year after transplantation among 2761 SOT recipi-
ents in Switzerland.
METHODS
Characteristics of the STCS
The STCS prospectively enrolls all SOT recipients undergoing 
transplantation in Switzerland [8]. Designed as a patient-case 
system, the database captures both patient- and graft-specific 
data. Clinical and laboratory data are continuously collected 
and entered in the database at the time of transplantation, at 6 
and 12 months, then yearly thereafter. The STCS Central Data 
Center performs regular data monitoring and in-depth data 
quality audits. In this process, all participating centers and all 
types of transplants are assessed by a thorough review process 
of randomly sampled patients. Ethics approval was obtained 
in all participating centers; all enrolled patients gave written 
informed consent. The study was approved by the Scientific 
Committee of the STCS, which granted permission to the in-
vestigators to use the data from the STCS.
Patients
All adult recipients of lung, heart, liver, kidney, and kidney-
pancreas grafts in Switzerland and enrolled in the STCS be-
tween 1 May 2008 and 31 December 2014 were included.
Infections
All infections were identified by transplant–infectious disease 
(TID) physicians using electronic hospital records and referral 
documentation for both inpatients and outpatients in inter-
vals ranging from twice a week to every 3 months, according 
to standardized definitions (Supplementary Data). The defin-
itions were developed by the STCS infectious diseases working 
group, based on recommendations and guidelines proposed 
by the American Society of Transplantation Infectious Disease 
Community of Practice, and the European Conference on 
Infections in Leukemia [9, 10]. Particular care was taken to 
minimize the risk of miscoding colonization as “infection.” To 
reduce the risk of intraobserver variability, randomly selected 
infections were evaluated by TID physicians during a quality 
review. In the present study, we considered as clinically relevant 
infections all proven bacterial, probable and proven fungal, and 
probable and proven viral infections, as well as viral syndromes 
(Supplementary Data).
Data on antimicrobial resistance were recorded by the STCS 
after August 2012. Multidrug resistance was defined according 
to international standards [11]. Infections in patients hospital-
ized for <24 hours were collected as outpatient infections.
Immunosuppression and Prophylaxis
Immunosuppressive and preventive strategies were center spe-
cific and varied according to transplant (Supplementary Figures 
1 and 2). All patients received peritransplant antibacterial pro-
phylaxis for 48 hours, as well as oral nystatin prophylaxis for 
14  days. To be recorded, prophylaxis required administration 
exceeding 48 hours and had to be targeted to prevent specific 
pathogens.
Outcomes
The primary outcome was occurrence of clinically relevant 
infections within 12  months posttransplantation. Secondary 
outcomes included type of pathogen, time of infection, and dis-
tribution according to transplant type and infection sites.
Statistical Analysis
Time of observation was calculated for each patient as time 
between transplantation and dropout, second transplant, or 
return to dialysis, death, or censoring date, whichever oc-
curred first. Patients with graft failure leading to second 
transplantation were censored at the time of their second 
transplantation. Kidney transplant recipients returning to di-
alysis are censored from the STCS follow-up. Infection rates 
per person-time were calculated as the number of infections 
during the first year posttransplantation divided by person-
time. Because the highest infection density was observed 
within 50 days posttransplantation, differences in cumulative 
incidences in infections were calculated at 49 days. Infection 
rates per 1000 transplant-days were calculated for each time 
span (during first month, >1–6 months, >6–12 months) in a 
negative binomial model.
RESULTS
Transplant Population and Incidence of Infections
Of 3541 lung, heart, liver, kidney, and kidney-pancreas trans-
plant recipients since 1 May 2008 in Switzerland, 3304 patients 
(93%) consented to participate in the STCS (Supplementary 
Figure 3). Of these, 2761 patients had their first SOT between 
1 May 2008 and 31 December 2014 and were included in this 
analysis. Patients received kidney (n  =  1612 [58%]), liver 
(n = 577 [21%]), lung (n = 286 [10%]), heart (n = 213 [8%]), 
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and kidney-pancreas (n  =  73 [3%]) transplants (Table 1). 
During the first year posttransplantation, 80% (2210/2761) 
of these patients had 8562 infectious events recorded. A total 
of 3520 events in 1520 patients (55%) fulfilled the criteria for 
clinically relevant infections, further designated as infections. 
The infection rate per person-year was 1.3 (95% confidence 
interval [CI], 1.3–1.4). Of patients at risk, 27% (755/2761) had 
989 infections (28% of all infections) during the first month 
(12.0 episodes per 1000 transplant-days), 33% (906/2714) 
had 1553 infections (44%) between 1 and 6 months (3.9 epi-
sodes per 1000 transplant-days), and 23% (609/2649) had 
962 (28%) infections between 6 and 12  months following 
transplant (2.0  episodes per 1000 transplant-days) (Table 1; 
Supplementary Table 1). Infection rates were highest during 
the first month in heart (19.3 episodes per 1000 transplant-
days) and lung (17.3 episodes per 1000 transplant-days) 
transplant recipients and remained highest in lung transplant 
recipients between 6 and 12 months (2.6 infections per 1000 
transplant-days). Cumulative incidences varied by transplant 
type, with kidney transplant recipients having the lowest in-
cidence of infections (12% and 27% at day 14 and 7 weeks, 
respectively) as compared to recipients of heart (hazard ratio 
Table 1. Characteristics of Patients, Infections, and Antimicrobial Prophylaxis
Characteristic Heart Kidney Kidney-Pancreas Liver Lung Total
Patient characteristics       
 Transplantations 213 (8) 1612 (58) 73 (3) 577 (21) 286 (10) 2761 (100)
 Median age at transplantation, y (IQR) 52 (38–60) 54 (43–63) 44 (39–51) 54 (44–61) 54 (38–61) 54 (42–62)
 Male sex 160 (75) 1034 (64) 39 (53) 382 (66) 143 (50) 1758 (64)
 Any infectious event 167 (78) 1303 (81) 65 (89) 457 (79) 218 (76) 2210 (80)
 Any clinically relevant infection 128 (60) 852 (53) 44 (60) 320 (56) 176 (62) 1520 (55)
 Deaths (by infection) 32 (7) 41 (12) 1 (0) 57 (24) 30 (9) 161 (52)
Infections       
 Overall infections       
  Clinically relevant, No. 278 1964 90 725 463 3520
 Rate per 1000 transplant-days (95% CI)       
  0–1 mo 19.3 (15.7–23.8) 8.3 (7.5–9.2) 15.3 (10.9–21.4) 16.4 (14.3–18.8) 17.3 (14.4–20.7) 12.0 (11.1–12.8)
  >1–6 mo 3.9 (3.0–5.0) 3.9 (3.5–4.3) 3.5 (2.2–5.7) 3.3 (2.7–3.9) 4.6 (3.8–5.6) 3.9 (3.6–4.2)
  >6–12 mo 1.5 (1.1–2.2) 2.1 (1.9–2.4) 1.4 (.8–2.3) 1.7 (1.3–2.2) 2.6 (2.1–3.2) 2.0 (1.8–2.2)
 Rate per person-years (95% CI) 1.5 (1.3–1.7) 1.2 (1.2–1.3) 1.3 (1.0–1.5) 1.3 (1.2–1.4) 1.7 (1.6–1.9) 1.3 (1.3–1.4)
 Bacterial infections 152 (55) 1299 (66) 59 (66) 425 (59) 267 (58) 2202 (63)
 Viral infections 89 (32) 551 (28) 21 (23) 240 (33) 138 (30) 1039 (30)
 Fungal infections 36 (13) 104 (5) 10 (11) 56 (8) 57 (12) 263 (8)
 Parasitic infections 1 (.4) 10 (.6) 0 4 (.6) 1 (.3) 16 (.5)
Antimicrobial prophylaxis       
 Antipneumocystis       
  TMP-SMX 184 (86) 1495 (93) 67 (92) 383 (66) 274 (96) 2403 (87)
  Atovaquone 4 (2) 37 (2) 3 (4) 7 (1) 22 (8) 73 (3)
  Pentamidinea 2 (1) 29 (2) 0 7 (1) 1 (0.4) 39 (1)
 Antibacterial       
  ß-lactam 14 (7) 258 (16) 12 (16) 129 (22) 75 (26) 488 (18)
  Macrolides 0 5 (0.3) 0 1 (0.2) 36 (13) 42 (2)
  Quinolones 5 (2) 252 (16) 1 (1) 38 (7) 46 (16) 342 (12)
  Tobramycina 0 0 0 0 29 (10) 29 (1)
 Antiviral       
  Acyclovir/valacyclovir 15 (7) 82 (5) 2 (3) 24 (4) 120 (42) 243 (9)
  Gancyclovir/valgancyclovir 109 (51) 847 (53) 49 (67) 172 (30) 225 (79) 1402 (51)
  Lamivudine 4 (2) 27 (2) 0 14 (2) 6 (2) 51 (2)
 Antifungal       
  Fluconazole 1 (1) 11 (0.7) 7 (10) 20 (4) 4 (1) 43 (2)
  Mold-active azolesb 0 11 (1) 0 11 (2) 195 (68) 217 (8)
  Echinocandinsc 1 (1) 2 (0.1) 0 22 (4) 17 (6) 42 (2)
  Amphotericin Ba 8 (4) 31 (2) 1 (1) 19 (3) 234 (82) 293 (11)
Data are presented as no. (%) unless otherwise indicated.
Abbreviations: CI, confidence interval; IQR, interquartile range; TMP-SMX, trimethoprim-sulfamethoxazole.
aBy aerosol.
bMold-active azoles: itraconazole, voriconazole, and posaconazole.
cEchinocandins: caspofungin and anidulafungin.
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[HR], 1.83 [95% CI, 1.44–2.31]; P  <  .001), liver (HR, 1.66 
[95% CI, 1.42–1.95]; P < .001), and lung (HR, 1.68 [95% CI, 
1.35–2.09]; P <  .001) transplants (Figure 1A). At 12 months 
posttransplantation, the cumulative incidence reached 53% 
for kidney, 55% for liver, 60% for heart and kidney-pancreas, 
and 62% for lung transplant recipients. Given the small 
number of parasitic infections (16), these were not included 
in further subanalyses. For 161 (6%) patients, the follow-up 
terminated before 12  months because of death, and only 6 
patients were lost to follow-up. Infections were recorded as 
direct cause of death in 52 (2%) patients (Table 1).
Types and Duration of Prophylaxis
In the first year posttransplantation, prophylaxis was given to 
2617 (95%) SOT recipients. Anti-Pneumocystis prophylaxis 
included trimethoprim-sulfamethoxazole, prescribed to 87% 
of patients (2403/2761) for a median duration of 179 days (in-
terquartile range [IQR], 119–281 days; Table 1; Supplementary 
Figure 2). Antibacterial prophylaxis provided to 27% of patients 
(754/2761) included β-lactam antibiotics (488 patients; median 
duration, 8  days [IQR, 2–32  days]) and quinolones (342 pa-
tients; median duration, 12  days [IQR, 7–35  days]). Antiviral 
prophylaxis provided to 57% of patients (1569/2761; median 
Figure 1. Incidence and distribution of clinically relevant infections by allograft type in 2761 solid organ transplant (SOT) recipients. A, Cumulative incidence censored for 
competing events (proven infection, graft loss, death, second transplantation) of first clinically relevant infections by allograft type until week 7 after SOT. B, Relative per-
centage of clinically relevant infections with predominant pathogens by allograft type.
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duration, 95  days [IQR, 59–180  days]) included 98% of lung 
transplant recipients. Ganciclovir/valganciclovir was given to 
51% (1402/2761) patients. Antifungal prophylaxis was infre-
quently prescribed (18% [487/2761] of all SOT recipients) and 
was mostly administered to lung transplant recipients (median 
duration, 358 days [IQR, 34–362 days]).
Burden of Clinically Relevant Infections
Bacterial infections predominated, causing 63% (2202/3520) 
of all infections (Table 1; Figure 1B). Thirty-nine percent 
(1086/2761) of patients developed at least 1 proven bacte-
rial infection. Hepatic and other intra-abdominal infections 
(158/450 [35%]) predominated in liver recipients, whereas 
the urinary (938/1355 [69%]) and respiratory tracts (143/273 
[52%]) were most frequently involved in kidney and lung 
transplant recipients, respectively (Figure 2A). Bacteremia 
was documented in 18% (405/2202), with 22% (89/405) 
occurring between 6  and 12  months after transplantation 
(Supplementary Table 2). Enterobacteriaceae were identified 
in 54% (1194/2202) of infections (Figure 1B; Supplementary 
Table 1; Supplementary Figures 4 and 5), with Escherichia 
coli and Klebsiella spp predominating (1033/2202 [47%]). 
Fifteen percent (65/449) of tested E.  coli and Klebsiella 
spp produced extended-spectrum β-lactamases (ESBL), 
whereas no carbapenemase-producing bacteria were de-
tected. Enterococcus spp and Pseudomonas aeruginosa were 
responsible for 20% (439/2202) and 9% (200/2202) of infec-
tions, respectively. Twenty-three percent (17/74) of tested 
P. aeruginosa isolates were multidrug resistant. Staphylococcus 
aureus (79/2202 [4%]) and Clostridioides difficile (111/2202 
[5%]) were infrequent pathogens. Opportunistic bacteria, 
such as Legionella spp, Nocardia spp, and Mycobacteria spp, 
were responsible for 0.6% (14/2202) of infections.
Thirty percent of all infections (1039/3520) were viral, in-
cluding 77 viral syndromes, 314 probable viral infections, 
and 648 proven viral infections (Table 1; Figure 1B). Except 
for lung transplant recipients, in whom respiratory tract in-
fections predominated (107/133 [80%]), sites of viral in-
fections were similar across different transplantations and 
consisted of mucocutaneous (239/1039 [23%]), respira-
tory tract (233/1039 [22%]), and intra-abdominal/hepatic 
(228/1039 [22%]) infections (Figure 2A; Supplementary 
Figures 6 and 7). Herpesviruses predominated (528/1039 
[51%]). Cytomegalovirus (CMV) presented as viral syndrome 
(n = 69), probable infection (n = 57), and proven (n = 76) in-
fection, altogether 5.7% (202/3520) of all clinically relevant in-
fections, BK polyomavirus viremia was seen in 275 (275/1685 
[16%]) and diagnosed as probable (n = 39) and proven neph-
ropathy (n  =  60) in 6% (99/1685) of kidney and kidney-
pancreas transplant recipients, constituting 17% (99/572) of 
viral infections in these patients.
Fungus caused 170 proven and 93 probable infections, rep-
resenting 8% (263/3520) of all clinically relevant infections 
(Table 1; Figure 1B). The respiratory tract was affected in 
34% (88/263) and predominated in lung transplant recipients, 
whereas intra-abdominal/hepatic infections predominated in 
kidney-pancreas and liver transplant recipients (Figure 2A). 
Fungemia and central nervous system involvement were docu-
mented in 3% (17/263) and 2% (6/263), respectively. Candida 
spp predominated (160/263 [60%]) and prevailed in liver trans-
plant recipients (52/56 [93%]) (Supplementary Figures 8 and 9). 
Nineteen percent (50/263) of infections were due to Aspergillus 
fumigatus, affecting lung (20/50 [40%]) and kidney transplant 
recipients (14/50 [28%]), whereas Pneumocystis jirovecii infec-
tions (20/263 [8%]) occurred mainly in kidney transplant re-
cipients (15/20 [75%]) clustered in a single center that did not 
provide prophylaxis between 2008 and 2012 [12].
Timeline of Clinically Relevant Infections
Bacterial infections predominated during the entire year 
(Supplementary Figure 10). Infections due to Enterobacteriaceae 
occurred at high frequency throughout the observation period, 
whereas infections due to Enterococcus spp and nonfermenting 
gram-negative bacteria occurred at high rates during the 
first 180 and 150  days, respectively, and continued there-
after at reduced but still regular pace (Figure 2B). CMV and 
herpes simplex virus (HSV) infections peaked at 50 days and 
continued during the entire observation period. Respiratory 
virus infections (influenza, parainfluenza, respiratory syncy-
tial virus, human metapneumovirus, and rhinovirus) occurred 
throughout the first year posttransplantation. Aspergillus infec-
tions occurred primarily in the first 150 days, and Pneumocystis 
as isolated events between 50 and 350 days.
The timelines of clinically relevant infections differed between 
types of transplantations (Figures 3 and 4). Enterobacteriaceae, 
predominating during the entire year as urinary pathogens in 
heart, lung, and kidney transplant recipients, and as digestive 
digestive  tract pathogens in liver transplant recipients, were a 
major cause of bloodstream infections in kidney and liver trans-
plant recipients. Respiratory tract infections due to P. aeruginosa 
and Enterobacteriaceae were restricted to the first month in 
heart transplant recipients and occurred throughout the first 
year in lung and kidney transplant recipients. Enterococcus spp 
were frequent during the entire year as urinary tract pathogens 
in kidney and as tract pathogens in liver transplant recipients, 
and were frequently associated with bloodstream infections in 
liver transplant recipients. Candida albicans bloodstream infec-
tions were observed during the first month in liver and heart 
transplant recipients and were associated with digestive tract 
infections in liver transplant recipients. CMV and HSV infec-
tions occurred with similar timelines in kidney, liver, and heart 
transplant recipients.
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DISCUSSION
In 1998, Fishman and Rubin, the clinical pioneers of TID, 
distinguished 3 periods of infections following SOT: (1) 
nosocomial infections until 1  month posttransplantation; (2) 
opportunistic infections from 1  month to 6  months; and (3) 
community-acquired or persistent infections after 6  months 
Figure 2. Distribution by infection site and timeline of infections. A, Distribution (%) of 2202 clinically relevant bacterial, 263 fungal, and 1039 viral infections by infection 
site and allograft type. Percentages are normalized for each allograft type and represent the relative involvement of each site. B, Temporal distribution of clinically rele-
vant infections by pathogen. Each bar represents an individual event: bacterial (red), viral (blue), and fungal (green) infection. The number of patients under observation is 
indicated at specific time points. Other gram-positive bacteria: coagulase-negative staphylococci, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus spp. 
Enterobacteriaceae: Escherichia coli, Klebsiella spp, Enterobacter spp. Nonfermenting gram-negative bacteria: Pseudomonas aeruginosa, Burkholderia spp, Acinetobacter 
spp, Stenotrophomonas maltophilia. Opportunistic bacteria: Nocardia spp, Legionella spp, Mycobacteria spp other than tuberculosis. Herpesviruses include herpes simplex 
virus, varicella zoster virus, and human herpesviruses 6 and 8. Abbreviations: BKPyV, BK polyomavirus; CMV, cytomegalovirus; EBV, Epstein-Barr virus.
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[1]. This important timeline has successfully guided the admin-
istration of antimicrobial prophylaxis and the development of 
diagnosis-based preemptive strategies, as well as life-saving em-
piric therapies [3]. In this STCS covering comprehensively all 
clinically relevant infections over the first 12 months after SOT 
in >2700 patients, we found that (1) infections were frequent, 
occurring at high incidence even 6 months after transplant; (2) 
timelines of infections had organ specificities; (3) traditional 
opportunistic pathogens were rare and occurred throughout the 
12 months; and (4) bacteria predominated being responsible for 
>60% of all infections throughout the year. Thus, despite an in-
creased potency of immunosuppression in the current era, the 
impact of opportunistic infections could be at least partially 
counteracted through targeted prophylaxis, surveillance, and 
risk stratification spearheaded by Rubin and Fishman. Previous 
registries and clinical trials, focused on specific transplant 
populations, pathogens, or particular infection sites, provided 
limited data to determine the overall impact of these measures 
on the global burden of infections [7, 13–17]. Reports from the 
Spanish Network for Research on Infection in Transplantation 
(RESITRA) cohort suggested a decline in incidence of inpatient 
infections from 8.3 episodes per 1000-transplant-days  during 
the first month to 0.4 episodes per 1000 transplant-days be-
tween 6 and 12 months after SOT [4, 5]. However, relevant in-
fections occurring at distant hospitals, or as outpatients, were 
not captured.
The extensive medical network in Switzerland allows a very 
close medical follow-up, with all infections occurring during 
hospitalization or as outpatients being taken care of and docu-
mented in the transplant center. Furthermore, particular care 
was taken in the STCS to assure optimal data quality, based 
on standardized definitions and quality audits. Consequently, 
AQ17AQ16
Figure 3. Timelines of the most significant clinically relevant infections for heart (A) and lung (B) transplant recipients according to predominant infection sites. The 
timeline and relative burden are based on the temporal distribution of 278 infections in 213 heart transplant recipients and 463 infections in 286 lung transplant recipients. 
Abbreviations: CMV, cytomegalovirus; HSV, herpes simplex virus; VZV, varicella zoster virus.
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our data guarantee a comprehensive view of all clinically rele-
vant infections during the first year following transplantation. 
Unlike previous reports, the overall burden of infection in this 
cohort remained elevated during the entire year. Twenty-four 
percent of patients at risk between 6 and 12 months post-SOT 
developed 28% of all infections, with an incidence of 2 infec-
tions per 1000 transplant-days. Forty-seven percent of these late 
infections required hospitalization, underlying their severity. As 
previously suggested by others, our study demonstrates the effi-
cacy of present antimicrobial prophylaxis against opportunistic 
pathogens [4, 18]. Indeed, we observed a low number of op-
portunistic infections in all types of SOT recipients frequently 
occurring at later timepoints following transplantation, once 
prophylaxis is discontinued. Better defining populations at risk 
for these opportunistic infections will be crucial to further im-
prove the present prophylactic strategies, mostly designed for 
early infections [12, 19–26]. Aspergillus fumigatus, responsible 
for 1.4% of all infections, is a serious concern, particularly in 
liver transplant recipients, because of the associated high mor-
tality [26]. The scarcity of CMV disease, presenting a bimodal 
distribution, reflects the success and shortcomings of prophy-
lactic and preemptive strategies used in Switzerland [27]. This 
calls for additional efforts to better define timing to discontinue 
prophylaxis, potentially by testing specific cell-mediated im-
munity against CMV [28]. HSV and varicella zoster virus are 
the most frequently encountered viral infections; with HSV-
seropositive heart and liver transplant recipients not receiving 
CMV prophylaxis being at highest risk. Their burden should be 
balanced with the level of morbidity, drug toxicity, and costs 
of widened prophylaxis in new recommendations [29]. BK 
polyomavirus nephropathy, diagnosed in 3.6% of kidney and 
kidney-pancreas recipients, has emerged as a concern because 
of its serious consequences in kidney-transplant recipients 
[30–32].
Figure 4. Timelines of the most significant clinically relevant infections for kidney (A) and liver (B) transplant recipients according to predominant infection sites. The time-
line and relative burden are based on the temporal distribution of 1964 infections in 1612 kidney and 725 infections in 577 liver transplant recipients. Abbreviations: BKPyV, 
BK polyomavirus; CMV, cytomegalovirus; HCV, hepatitis C virus; HSV, herpes simplex virus; VZV, varicella zoster virus.
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Our study further highlights the preponderance of bacte-
rial pathogens. Infections due to Enterobacteriaceae (E.  coli, 
Klebsiella spp), P. aeruginosa, and Enterococcus spp, previously 
described as being limited to the first month predominated, 
throughout the entire year. Together these microorganisms were 
responsible for 48% of all infections. In contrast to previous re-
ports, suggesting that bloodstream infections rarely occur after 
180 days post-SOT, we found a persisting high frequency of bac-
teremia with 22% of all episodes occurring after 6 months [7]. 
Preventing these infections will be a major challenge. Indeed, 
many of these infections involve the surgical site and the allo-
graft itself, and are favored by surgical complications including 
anastomotic leaks and strictures, undrained collections, and 
indwelling catheters [3, 33, 34]. Major efforts to reduce these 
risk factors, including improved surgical techniques, adequate 
source control, and early removal of indwelling catheters and 
prosthetic material will be essential. Infections with ESBL- 
and carbapenemase-producing E.  coli and K.  pneumoniae, 
multidrug-resistant and pan-drug-resistant P.  aeruginosa, and 
vancomycin-resistant enterococci are on the rise worldwide 
and affect SOT recipients, with an important impact on survival 
[15, 35–40]. The major burden represented by these particular 
bacterial species in SOT recipients in our study is particularly 
alarming. Switzerland currently has a rather low incidence of 
bacterial resistance compared with other countries. The rates 
of multidrug-resistant bacterial infection in our cohort should 
therefore serve as a caution to transplant programs in other 
countries where resistance rates may be even higher [41, 42]. 
Furthermore, clinicians initiating empiric therapies need to be 
aware about pathogen and infection timelines differences ac-
cording to type of transplant.
We wish to acknowledge potential limitations. Though we 
used concise definitions and unified identification proced-
ures, some infections might have been miscoded, thereby 
overestimating some infections. Due to the inclusion of micro-
biologically documented infections, difficult-to-authenticate 
infections (ie, respiratory tract infections) might have been 
underrepresented. Despite efforts to identify all inpatient and 
outpatient events, we cannot exclude that some infections 
were not captured and hence underestimated. Kidney trans-
plant recipients represented 61% of our population, potentially 
influencing the rates of disease manifestations. However, cap-
turing infections in a large number of non–kidney transplant 
recipients during the same era revealed similar trends among 
different pathogen types and infection rates, strengthening the 
robustness of our observations. Our study was not designed to 
determine the risk of infections in the presence or absence of 
antimicrobial prophylaxis, or potential associations between in-
fections. Finally, the results of our study may not be applicable 
to programs in other geographic settings, having different mi-
crobial epidemiology and prophylaxis strategies.
CONCLUSIONS
Certain aspects of the 1998 TID timeline remain true in the cur-
rent era of potent immunosuppression, screening, and prophy-
laxis. Translating the TID timeline into prophylactic strategies, 
the incidence of opportunistic infections has been reduced and 
partly shifted to later timepoints. The first month remains char-
acterized by the highest burden of infections, with healthcare-
associated infections prevailing. However, bacterial infections, 
mainly affecting the allograft and transplant site, continue at 
high rates throughout the entire year, urging for better con-
trol. The transplant-specific timelines presented here should 
help clinicians to target patient-adapted prophylactic and 
empiric treatments. The high burden of Enterobacteriaceae, 
Pseudomonas, and Enterococcus with rising antimicrobial re-
sistance is worrisome and urges for the development of new ap-
proaches and antimicrobials to guarantee improved graft and 
patient survival.
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